Searched for
PHARMA SECTOR OUTLOOK
Stock picks of the week; 5 stocks with consistent score improvement and upside potential of up to 25%Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...
100 days of Iran war, Rs 4,50,000 crore wiped out: Is your stock portfolio safe from missiles?Indian equities have lost Rs 4.5 lakh crore in 100 days as the Iran-led West Asia conflict and a global AI trade unwind trigger sharp FII o...
Q4 FY26 earnings: Metal companies lead growth, backed by robust volumes and favourable pricing trendsET Wealth presents an 8-quarter earnings assessment report of various sectors. The year-on-year net profit growth for 18 sectors is present...
Dalal Street Week Ahead: Will Nifty hold 23,000 as markets test key support?The markets ended lower this week, with Nifty trading below its 50 and 100-week moving averages. While a crucial support zone near 23,000-2...
These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
Market correction nearing its end; bet on banking, pharma: Rohit SrivastavaMarket correction may be nearing its end, with Nifty approaching a key support zone around 23,077. Banking, energy, and metals sectors show...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...
Pankaj Pandey identifies defence, pharma and consumption as core stock picking themesIndian equities face a mixed outlook due to potential monsoon deficit and uneven corporate earnings. While rural-linked sectors may see pre...
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
20 months of bearish markets: One additional letter that tells you which 'cheap' stocks are actually cheapMost investors live by one ratio. That ratio that tells them all they want to know – or should one say all they want to hear? They open a s...
Dalal Street Week Ahead: Nifty stuck in consolidation zone; 23,800 remains key breakout hurdleMarkets experienced volatility and ended the week with a modest loss, primarily due to MSCI rebalancing flows. Nifty consolidated within a ...
Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...
Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
30 Nifty stocks wipe out Rs 22.64 lakh crore investor wealth in 2026 so far; HDFC Bank, TCS lead routThirty Nifty 50 stocks have wiped out Rs 22.64 lakh crore in investor wealth this year. HDFC Bank and TCS led the decline, losing Rs 3.55 l...
6 pharma stocks that Bernstein sees up to 40% upside potential. Do you own any?Bernstein initiated coverage on six pharma stocks, expressing a positive outlook on the Indian healthcare sector driven by AI, innovation i...
Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
June quarter earnings to determine market direction, says Sunil Subramaniam, warns on risks in near termMarket expert Sunil Subramaniam advised caution amid geopolitical uncertainty and rising input costs, while favouring consumer durables, ca...
Markets to enter prolonged “drag phase,” not deep correction: Vikas KhemaniMarket expert Vikas Khemani anticipates a consolidation phase for Indian equities rather than a sharp breakout, citing persistent global ma...
Bank Nifty near key resistance zone; breakout above 54,300 crucial: Ajit MishraIndian equity markets are consolidating within a narrow range, with Nifty struggling to break 24,000 and Bank Nifty showing relative streng...
Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...